Takara Bio Inc.
Other OTCTotal Valuation
Takara Bio Inc. carries a market capitalization of 879.03M, placing it among publicly traded companies globally. Its enterprise value stands at -39.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 879.03M |
| Enterprise Value | -39.62B |
Share Statistics
Takara Bio Inc. currently has 120.42M shares outstanding.
| Shares Outstanding | 120.42M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Takara Bio Inc. maintains a current ratio of 9.51, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.51 |
| Quick Ratio | 5.96 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 144.73 |
Financial Efficiency
Takara Bio Inc. posts a return on equity of 0.59 and a return on invested capital of 0.45.
| Return on Equity (ROE) | 0.59 |
| Return on Assets (ROA) | 0.32 |
| Return on Invested Capital (ROIC) | 0.45 |
| Return on Capital Employed (ROCE) | 0.57 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.88 |
Taxes
Over the trailing twelve months, Takara Bio Inc. has paid 854.00M in income taxes, reflecting an effective tax rate of 67.51.
| Income Tax | 854.00M |
| Effective Tax Rate | 67.51 |
Stock Price Statistics
Takara Bio Inc.'s stock has declined approximately -68.53448% over the past 52 weeks. The 50-day moving average sits at 7.30, while the 200-day moving average is 13.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -68.53448% |
| 50-Day Moving Average | 7.30 |
| 200-Day Moving Average | 13.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Takara Bio Inc. generated 24.39B in revenue and converted that into 396.00M in net income, yielding earnings per share of 3.42. EBITDA reached 1.59B, while operating income came in at 1.59B.
| Revenue | 24.39B |
| Gross Profit | 13.57B |
| Operating Income | 1.59B |
| Pretax Income | 1.27B |
| Net Income | 396.00M |
| EBITDA | 1.59B |
| EBIT | 1.59B |
| Earnings Per Share (EPS) | 3.42 |
Balance Sheet
Total book value stands at 66.90B, with working capital of 57.06B providing operational flexibility.
| Cash & Cash Equivalents | 39.96B |
| Total Debt | N/A |
| Net Debt | -39.96B |
| Equity (Book Value) | 66.90B |
| Book Value Per Share | 555.92 |
| Working Capital | 57.06B |
Cash Flow
Takara Bio Inc. produced -376.00M in operating cash flow over the past twelve months. After subtracting -1.44B in capital expenditures, free cash flow totaled -1.82B - equivalent to -15.10 per share.
| Operating Cash Flow | -376.00M |
| Capital Expenditures | -1.44B |
| Free Cash Flow | -1.82B |
| FCF Per Share | -15.10 |
Margins
Takara Bio Inc. operates with a gross margin of 55.62, reflecting its pricing power and cost economics. The operating margin of 6.53 and net profit margin of 1.62 provide insight into operational efficiency.
| Gross Margin | 55.62 |
| Operating Margin | 6.53 |
| Pretax Margin | 5.19 |
| Profit Margin | 1.62 |
| EBITDA Margin | 6.53 |
Dividends & Yields
The company's payout ratio of 1.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | 1.17 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
Takara Bio Inc. posts an Altman Z-Score of 1.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.46 |